Cure8 trial brief
This study explores a non-drug dietary supplement approach aimed at changing host–microbiome interactions after surgery — a potentially relevant prevention strategy for postoperative Crohn's disease recurrence if later proven effective.
Adults with Crohn's disease who have recently undergone ileal or ileocecal resection, clinicians managing postoperative recurrence, and researchers interested in microbiome- or glycome-targeted interventions.
This is a proof-of-concept, single-arm dietary-supplement study enrolling about 30 adults after ileal or ileocecal resection. Participants will receive an orally administered glycan and be followed for up to 6 months after surgery to assess microbial and immunological changes.
The protocol excludes patients who start antibiotics, aminosalicylates, immunomodulators, biologics, or small molecules for postoperative recurrence during the study window, and excludes several other groups (pregnant/lactating people, prior resections in most cases, allergy to glycans, uncontrolled diabetes, bleeding disorders, etc.).
The trial is recruiting at a site in Lisbon, Portugal. The record reports planned outcomes focused on microbial and immunological (biomarker) changes rather than clinical endpoints.
This is a registered interventional trial (single-arm, proof-of-concept) with planned enrollment of ≈30 participants and biomarker-focused outcomes over 6 months. As a trial record, it describes the planned study design and eligibility but does not provide results or evidence of clinical benefit.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Dietary components and processed vegetarian/vegan products may alter the gut microbiome and intestinal barrier — both are relevant to IBD. This study will directly compare common vegan products and meat substitutes with...
If sodium intake influences gut proteolytic activity, microbiota and inflammation, the findings could help tailor dietary guidance and personalized nutrition strategies for people with Crohn’s disease.
This trial tests a safe, non-drug supplement (GlcNAc) as a precision-medicine approach for Crohn's disease based on a genetic variant that affects glycosylation. If successful, it could offer a new, well-tolerated...
